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Background: Lung cancer is a complex polygenic disease. Although recent genome-wide association (GWA)
studies have identified multiple susceptibility loci for lung cancer, most of these variants have not been validated in
a Chinese population. In this study, we investigated whether a genetic risk score combining multiple.
Methods: Five single-nucleotide polymorphisms (SNPs) identified in previous GWA or large cohort studies were
genotyped in 5068 Chinese case–control subjects. The genetic risk score (GRS) based on these SNPs was estimated
by two approaches: a simple risk alleles count (cGRS) and a weighted (wGRS) method. The area under the receiver
operating characteristic (ROC) curve (AUC) in combination with the bootstrap resampling method was used to
assess the predictive performance of the genetic risk score for lung cancer.
Results: Four independent SNPs (rs2736100, rs402710, rs4488809 and rs4083914), were found to be associated with
a risk of lung cancer. The wGRS based on these four SNPs was a better predictor than cGRS. Using a liability
threshold model, we estimated that these four SNPs accounted for only 4.02% of genetic variance in lung cancer.
Smoking history contributed significantly to lung cancer (P < 0.001) risk [AUC = 0.619 (0.603-0.634)], and
incorporated with wGRS gave an AUC value of 0.639 (0.621-0.652) after adjustment for over-fitting. This model
shows promise for assessing lung cancer risk in a Chinese population.
Conclusion: Our results indicate that although genetic variants related to lung cancer only added moderate
discriminatory accuracy, it still improved the predictive ability of the assessment model in Chinese population.
Keywords: Chinese, Cumulative risk, Genetic risk score, Lung cancer, Risk assessmentBackground
Lung cancer is one of the leading causes of cancer death
worldwide [1,2]. Most patients are diagnosed at an
advanced stage, so are not able to undergo surgical
removal of tumors [1]. As a result, the overall 5-year
survival rate is low. Early stage detection when treat-
ment might be more effective, would therefore help
reduce lung cancer mortality. For this reason, a well-
established assessment model that could identify* Correspondence: wwm1970@hotmail.com; darulu@hotmail.com
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clinicians and researchers.
Lung cancer is a polygenic disease, for which many gen-
etic factors appear to play an important role in disease de-
velopment [2,3]. During the past three years, several
genome-wide association (GWA) studies have identified a
number of genetic susceptibility loci associated with lung
cancer risk [4-9], but most of these studies were con-
ducted in populations of European descent, and many
identified risk alleles have not been adequately evaluated
in Asian populations.
In addition, when examined individually, each of the
genetic susceptibility loci only confers a small to moderate
disease risk, and is of limited utility in risk prediction. It is
possible that combining multiple disease-related loci with
modest effects into a genetic risk score (GRS) may be use-
ful to identify subgroups that are at high risk of lunghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have been proposed, including the Bach model, Spize
model, and Liverpool Lung Project (LLP) model [12-15].
However, most predictors from these models focus on
demographic and clinical factors, and, to our knowledge,
no report has quantified the risk of lung cancer using a
combination of newly identified risk loci in a Chinese
population.
In this case–control study, we evaluate the discrimin-
atory and predictive ability of the cumulative effect of
several SNPs associated with lung cancer risk in popula-
tions of European descent, and estimate the proportion
of genetic variants explained by the selected risk loci in
a Chinese population.Methods
Subjects
A total of 2,283 lung cancer cases and 2,785 cancer-free
controls (from Shanghai Zhongshan Hospital, Shanghai
Chest Hospital, First Affiliated Hospital of Nanjing Med-
ical University, Beijing Union Medical College Hospital,
and Wuhan Union Hospital, China) who were genetically
unrelated Han Chinese were enrolled in this study. Eligible
patients had histopathologically confirmed lung cancer,
and with no previous cancer history and were no receiving
radiotherapy or chemotherapy for other condition. Con-
trol participants were randomly selected from individuals
receiving routine physical examinations in local hospitals
or those who participated in a community-based screen-
ing program of non-communicable diseases. They were
frequency-matched to the cases according to age, gender
and residential area.
Information on smoking was collected by means of
interviews. Individuals who had smoked less than one
cigarette per day for less than one year of their lifetime,
or less, were defined as nonsmokers. The remaining
individuals were divided into light and heavy smokers
according to the threshold of 25 pack years (median
pack years in the controls). All participants provided
written informed consent for study participation with
approval from institutional review boards of each partici-
pating institution.Table 1 Selected SNPs associated with lung cancer*
First author, year (reference) SNP Gene Chromoso
McKay, 2008 [4] rs2736100 TERT 5p15
McKay, 2008 [4] rs402710† CLPTM1L 5p15
McKay, 2008 [4] rs1051730 CHRNA 5, CHRNA 3 15q25
You, 2009 [24] rs4083914 RGS17 6q23-25
Miki, 2010 [23] rs4488809 TP63 3q28
*Characteristics of the loci from the cited genome-wide association and fine-mappi
†Rs402710 showed relatively litter LD with rs2736100 (D’ = 0.020).
‡ Odds ratio per copy of the risk allele, as reported in the cited study.Selection of genetic risk factors and genotyping
We reviewed the literature on GWAS and large cohort
studies published up until June, 2011, and selected those
lung cancer risk SNPs from GWAS demonstrating p <
5E-6 or from large cohort studies with evidence of repli-
cation at p < 0.05. In total, Five SNPs were selected for
analysis (Table 1).
Blood samples were collected from each subject at the
time of recruitment, and genomic DNA was extracted using
QIAamp DNA Maxi kit (Qiagen GmbH). All SNPs were
determined using the Sequenom MassARRAY iPLEX plat-
form using the matrix-assisted laser desorption/ionization
time-of-flight mass spectrometer (MALDI-TOF). Primer
sequences are available on request. Overall, more than 98%
of genotypes were successfully determined for all the SNPs;
5% of samples were randomly selected to re-genotype for
quality control, and showed a reproducibility of 100%.
Genetic risk score computation
Two approaches were used to calculate the genetic risk
score (GRS): a simple risk alleles count method (count
GRS, cGRS) and a weighted method based on the geno-
type frequencies for each SNP and effect sizes (allelic
odds ratio) from our study (weighted GRS, wGRS).
Based on the log-additive model, the three genotypes
AA, AB, and BB (A, low-risk allele; B, high-risk allele)
for an SNP had a relative risk of 1, OR and OR2,
respectively. If the B allele had frequency p, then the
average relative risk in the population is calculated as:
u = (1-p)2 + 2p (1-p) OR + p2OR2. The adjusted risk
values for AA, AB, and BB genotype were 1/u, OR/u,
and OR2/u2, respectively. Missing genotypes were
assigned a value of 1. The formula for our combined
SNP weighted risk score was: wGRS = SNP1 × SNP2 ×
SNP3 × SNP4, where SNP1-4 were weighted risk score
for individual SNPs.
Percentage of genetic variance explained
The percentage of genetic variance was estimated under
a liability threshold model [16]. Allele frequencies and
effect sizes corresponding to ORs were used to calculate
the threshold: [2p (1-p)] β2 (p, risk allele frequency; β,
additive allelic effect).mal location Genotyping rate Risk allele Reported OR (95% CI) ‡
99.5% C 1.18 (1.10-1.26)
99.6% C 1.22 (1.13-1.32)
98.8% T 1.35 (1.5-1.45)
99.7% G 1.80 (1.36-2.39)
100% T 1.27 (1.14-1.41)
ng studies. CI, confidence interval; OR, odds ratio.
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Logistic regression was employed to test the association
between genetic variants and lung cancer risk. The clas-
sification ability of the model was assessed using the area
under the receiver operating characteristic (ROC) curve
(AUC), known as a concordance (c) statistic. The
Hosmer-Lemeshow test was used to evaluate the calibra-
tion of risk estimated in our cohort data. Internal valid-
ation of models was carried out using a bootstrap
method involving 1000 replications to adjust model
parameters for potential over-fitting. A second validation
was performed by randomly dividing the cohort popula-
tion into two unequal groups (one with 75% of the
population, and the second with the remaining 25%).
The larger group (training set) was used to rebuild the
same model, which was then tested on the remaining
25% of the population (test set). All analyses were con-
ducted by Statistical Analysis System (SAS) software
(version 8.2; SAS Institute, Cary, NC). All p values were
two-sided, and p values < 0.05 were considered statisti-
cally significant.Results
Association between genetic risk alleles and lung cancer
Five lung cancer-associated SNPs identified in previous
GWA studies were evaluated in this study (Table 1).
Each SNP was in Hardy-Weinberg equilibrium (p >
0.05) in the control group. The results for the selected
risk alleles with lung cancer are shown in Table 2. Four
SNPs (rs2736100, rs402710, rs4083914, and rs4488809)
were significantly associated with lung cancer in our
study. Rs2736100 and rs402710 displayed weak linkage
disequilibrium (D’ = 0.022), but each was still associated
with lung cancer risk after adjusting for the other. The
four significantly associated SNPs were selected for fur-
ther analysis. A liability threshold model was used to es-
timate the percentage of genetic variation explained by
each of the risk alleles. Our data showed that rs2736100,
rs402710, rs4083914 and rs4488809 SNPs accounted for
1.33%, 0.40%, 0.47% and 1.82% of the genetic variance,
respectively (Table 2).Table 2 Association between SNPs and lung cancer
SNP PHWE Frequency of high-risk allele Obser
Rs2736100 0.49 0.41 1.18 (1
Rs402710 0.43 0.68 1.10 (1
Rs1051730 0.05 0.02 1.09 (0
Rs4083914 0.25 0.14 1.15 (1
Rs4488809 0.50 0.47 1.21 (1
NOTE: CI, confidence interval; OR, odds ratio.
*Odds ratio per copy of the high-risk allele.
†The percentage of genetic variance was estimated under a liability threshold modGenetic risk score association
Associations between lung cancer risk and genetic risk
score based on two methods (cGRS and wGRS) were
evaluated and the results are shown in Table 3. To esti-
mate the risk of genetic risk score, we calculated odds
ratios according to wGRS deciles. Compared with parti-
cipants who were in the lowest decile, those in the high-
est decile had a 2.01-fold (95% confidence interval (CI),
1.59-2.54; p < 0.001) increased risk of lung cancer. We
next compared the discriminative ability of GRS by cal-
culating the AUC, and wGRS was shown to be signifi-
cantly better than cGRS in lung cancer risk prediction
(Table 3 and Figure 1). The AUC was 0.551 for wGRS
versus 0.542 for cGRS (p < 0.001).Discrimination performance of wGRS × demographic
characteristics
General demographic characteristics (including age, gender,
smoking status) were analyzed (Table 3), and factor asso-
ciated with lung cancer risk (smoking history) was further
evaluated in the risk assessment model. The AUC value of
model that only has smoking was 0.619 (0.603-0.634). To
estimate the relative risk of lung cancer for individuals with
a given combination of risk factors, we used logistic regres-
sion to construct an assessment model including the wGRS
and smoking status. As shown in Table 4 and Figure 1,
the prediction model expressed as follows: OR = exp
(−0.9372 + 0.0610 × wGRS + 0.5142 × smoking status).
The AUC of full model was 0. 639 (p-value for discrimin-
ation difference of AUC values for wGRS <0.001; p-value
for discrimination difference of AUC values for smoking
status = 0.024). To correct for potential over-fitting, we
adjusted the model parameters using the bootstrap
method [17]. As the adjusted and unadjusted values were
almost the same, this indicated that there was little over-
fitting of the model.
The adjusted AUC for the full model described above
was 0.637 (Table 4 and Figure 1). The contribution of
wGRS to the model was 0.020 (assessed by the reduction
in c statistic when wGRS was removed from the full
model). Smoking status was the strongest predictor in
the model, with a contribution of 0.088.ved OR, (95% CI)* P Genetic variance explained†




.11-1.30) < 0.001 1.82%
el: [2p (1-p)] β2 (p, risk allele frequency; β, additive allelic effect).












cGRS (count risk allele)
0-1 125 (5.48) 226 (8.11) 1.00 (ref.) <0.001 0.542 (0.525-0.557)‡
2 337 (14.76) 465 (15.70) 1.31 (1.01-1.70) (0.540)*
3 589 (25.80) 733 (26.32) 1.45 (1.14-1.85)
4 600 (26.28) 740 (26,57) 1.47 (1.15-1.87)
5 435 (19.05) 453 (16.27) 1.74 (1.35-2.34)
≧6 197 (8.63) 168 (6.03) 2.12 (1.57-2.86)
wGRS (weighted genetic risk score)
0 (<Q10) 222 (9.72) 400 (14.36) 1.00 (ref.) <0.001 0.551 (0.532-0.564)‖
1 (Q10-Q20) 192 (8.41) 241 (8.65) 1.44 (1.12-1.84) (0.550)*
2 (Q20-Q30) 211 (9.24) 272 (9.77) 1.40 (1.10-1.78)
3 (Q30-Q40) 215 (9.42) 299 (10.74) 1.30 (1.02-1.65)
4 (Q40-Q50) 423 (18.53) 512 (18.38) 1.49 (1.21-1.83)
5 (Q50-Q60) 102 (4.47) 115 (4.13) 1.60 (1.17-2.19)
6 (Q60-Q70) 140 (6.13) 173 (6.21) 1.46 (1.11-1.92)
7 (Q70-Q80) 185 (8.10) 195 (7.00) 1.71 (1.38-2.22)
8 (Q80-Q90)) 309 (13.53) 323 (11.60) 1.72 (1.38-2.16)
9 (≧Q90)) 284 (12.44) 255 (9.16) 2.01 (1.59-2.54)
Age (mean±SD) 60.09±10.29 60.56±9.58
Age group
1 (≦60 year) 1113 (48.75) 1360 (48.53) 1.00 (ref.) 0.954 -
2(>60 year) 1170 (51.25) 1425 (51.17) 1.00 (0.90-1.12)
Gender
Male 1683 (73.72) 2039 (73.21) 1.00 (ref.) 0.686 -
Female 600 (26.28) 746 (26.79) 0.97 (0.86-1.11)
Smoking status
Never 801 (35.09) 1517 (54.47) 1.00 (ref.) <0.001 0.619 (0.603-0.634)※
Light-smokers 416 (18.22) 542 (19.46) 1.45 (1.25-1.70) (0.618)*
Heavy-smokers 1066 (46.69) 726 (26.07) 2.78 (2.45-3.16)
NOTE: CI, confidence interval; OR, odds ratio.
* Bootstrap optimism corrected estimate of model performance based on 1000 bootstrap resampling.
† Log-additive model.
‡ AUC value of model that only contain cGRS.
‡ AUC value of model that only contain wGS.
※AUC value of model that only contain smoking status.
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After the model was rebuilt on the training set, it dis-
played similar discrimination ability to the original one
(c statistic, 0.641). The model was then tested on the test
set, and also showed similar discrimination ability (c stat-
istic, 0.633).
We selected a cut-off value corresponding to the max-
imum sensitivity and specificity. Predictive performances
of the rebuilt model for defining a high risk group were
then assessed by sensitivity, specificity, accuracy, positive
predicted value (PV+) and negative predicted value (PV-)(Table 5). The predictive performances of this model in
the two separated groups were similar (accuracy of train-
ing set: 61.72%; accuracy of test set: 61.48%).
Discussion
In this study, we systematically evaluated the clinical
utility of five SNPs identified in recent GWAs and large
cohort studies of lung cancer. Using data from a large
case–control study that enrolled 5,068 participants, we
found that most of the genetic variants (rs2736100,
rs402710, rs4488809, and rs4083914) identified previously
Figure 1 Receiver operating characteristic curve for wGRS ×
smoking status and wGRS. Straight line indicates the null
discrimination. wGRS, weighted genetic risk score.
Table 5 Predictive performance of model
Dataset Accuracy Sensitivity Specificity PV+ PV-
Training set (75%) 61.72% 54.74% 67.53% 58.40% 64.18%
Test set (25%) 61.48% 52.57% 68.44% 56.52% 64.90%
Overall 61.66% 54.23% 67.76% 57.96% 64.36%
NOTE: PV+, Positive Predicted Value (true positive/ total predicted positive);
PV-, Negative.
predicted value (true negative/total predicted negative).
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cancer in a Chinese population. In addition, we showed
that a wGRS accounting for the adjusted effect size of
each SNP was a better predictor than a cGRS, and had a
stronger association with lung cancer risk than any single
SNP alone. Although the weighted genetic risk score had
a moderate predictive ability, it gave a better discrimin-
ation between lung cancer cases and cancer-free controls
(AUC of ROC curve, 0.639) when used in combination
with smoking status using the logistic regression model.
Several lung cancer risk assessment models have previ-
ously been proposed [12-15], but most predictors fo-
cused on traditional risk factors such as family history of
lung cancer, smoking status, environmental exposure,
age and gender. In contrast to these, genetic scores
derived from inherited genetic variations offer the ad-
vantage of stability during the lifetime of the individual.
Previous studies have indicated that inherited genetic
variants might account for an important fraction of lung
cancer developmental risk [18,19]. Recent GWA studies
of lung cancer in population of European ancestry iden-








ROC AUC/c statistics (95% CI) (BOC)* 0.639 (0.621-0.652) (
* Bootstrap optimism corrected estimate of model performance based on 1000 booCLPM1L), 15q25 (CHRNA 3–5) and 6p21 (BAT3-
MSH5) [4-9]. McKay et al. [4] reported two independent
markers of lung cancer at the 5p15 region, rs2736100
(TERT) and rs402710 (CLPM1L). Furthermore, an asso-
ciation between rs2736100 and lung cancer were also
replicated in Asian populations [20,21]. Of the five SNPs
evaluated in this study, we observed a strong signal at
rs2736100 in accordance with previous reports.
15q25 region encoding nicotinic acetylcholine receptor
subunits was thought to be related with lung cancer risk
[6-8]. We evaluated the rs1051730 SNP from this region
in the present study, but it showed no association with
disease risk. It is conceivable that the rs1051730 allele
frequency in the Chinese Han population (MAF, 0.02) is
too low to confirm the effects seen in European popula-
tions [22]. Reported risk SNPs at 6p21 (rs3117582 and
rs3131379) are not polymorphic in the Chinese Han
population, so were excluded from this study. Rs4488809
and rs4083914, previously identified by GWA and large
cohort investigations, were also shown to be significantly
associated with lung cancer risk in this study [23,24].
Of the five SNPs evaluated in this study, the strongest
signal was found for rs4488809, for which there was 21%
elevated risk of lung cancer with each risk allele. The
three other SNPs (rs2736100, rs402710, and rs4083914)
were also associated with a risk of lung cancer, albeit at
lower levels (<18%) for each risk allele. The estimated
proportion of genetic variation explained by these four
SNPs was therefore 4.02%, which includes 1.82% due to
rs4488809 and 1.33% due to rs2736100. This suggests
that the genetic susceptibility loci identified by GWA
and large cohort studies in other populations only confer
a small to moderate risk in a Chinese population whenstatus
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assessment.
To overcome this, a genetic risk score combining mul-
tiple loci might improve the identification of persons at
high risk for developing lung cancer. Our results showed
that although wGRS was highly associated with lung
cancer susceptibility, a model including wGRS alone did
not provide a better predictive capacity than a model in-
cluding traditional factors (c statistic for wGRS alone,
0.551). Smoking history was also associated with lung
cancer risk in this study, in agreement with previous
reports [12,25]. Moreover, wGRS, in combination with
smoking status showed a better predictive ability (c stat-
istic, 0.639). Indeed, the c statistic decreased by 0.020
when wGRS was removed from the full model, indicat-
ing that genetic risk factors could improve the dis-
criminatory ability of the traditional assessment model,
although this effect was moderate.
This study has a number of limitations. First, the sus-
ceptibility loci identified by GWA and large cohort stud-
ies with evidence of replication were associated with a
lung cancer risk through strong linkage disequilibrium,
and always conferred moderate effects. Many additional
susceptibility loci for lung cancer remain to be discov-
ered, and it is possible that rare variants with high pene-
trance would explain the remaining hereditary [26].
Next generation sequencing technologies offer hope in
the future research of such variants [27]. Recently, sev-
eral identified SNPs were reported [28-30]. Combining
these new SNPs might result in improvement in classifi-
cation of lung cancer risk. Second, because of limited
traditional factors, the full predictive model established
in this study only provided a moderate level of classifica-
tion accuracy, with a c statistic of 0.639, which is inad-
equate for risk prediction. The discriminatory capability
of our model might be improved by including additional
factors such as history of bronchitis, emphysema or
pneumonia, asbestos exposure, and family history of
lung cancer. Third, our assessment model lacked exter-
nal validation even though our estimates of ROC AUC
were corrected for over-fitting by bootstrap and internal
validation was conducted. Finally, as this was a retro-
spectively designed study, the results need to be vali-
dated by a large-scale, prospective study.
Conclusions
We have shown that most of the genetic susceptibility loci
identified by previous GWA and large cohort studies in
other populations were also associated with lung cancer
risk in a Chinese population. Although the weighted genetic
risk score had only a moderate discriminatory accuracy, it
still improved the predictive ability of the assessment
model, which might help in the identification of individuals
at a high risk of developing lung cancer. Future studiesshould focus on establishing a risk assessment model that
incorporates both genetic variants and established trad-
itional factors for lung cancer.
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